ASTRAZENECA PHARMACEUTICALS LP for ASTRAZENECA PHARMACEUTICALS LP
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Issues relating to Intellectual Property protections for Covid-19 treatments and vaccines.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSIE AHN | — |
| HELEN DWIGHT | — |
| AARON W HUNTER | — |
Health Issues HCR
Issues related to drug pricing. COVID-19 vaccine and therapy development.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSIE AHN | — |
| ELIZABETH BROOKS New | — |
| HELEN DWIGHT | — |
| THADDEUS FLOOD | — |
| AARON W HUNTER | — |
| CAROLINE QUAT | — |
| STEPHANIE WISWALL | — |
Medicare/Medicaid MMM
ANPRM International Pricing Index Model for Medicare Part B Drugs. Issues relating to Medicare Part D and Part B pricing reform. Issues related to Part B refunds for discarded amounts of certain single-dose container or single-use package drugs. H.R.1319, the American Rescue Plan Act (Section 9816, Sunset of Limit on Maximum Rebate Amount for Single Source Drugs and Innovator Multiple Source Drugs).
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSIE AHN | — |
| ELIZABETH BROOKS New | — |
| HELEN DWIGHT | — |
| THADDEUS FLOOD | — |
| AARON W HUNTER | — |
| CAROLINE QUAT | — |
| STEPHANIE WISWALL | — |
Pharmacy PHA
Issues related to the 340B drug discount program. Discussions related to an appropriations hold on funding for a 2014 FDA rule that would move package inserts (PI) from paper to digital form-e-labeling.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSIE AHN | — |
| ELIZABETH BROOKS New | — |
| HELEN DWIGHT | — |
| THADDEUS FLOOD | — |
| AARON W HUNTER | — |
| CAROLINE QUAT | — |
| STEPHANIE WISWALL | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.